PE20170286A1 - Diacuerpos heterodimericos biespecificos y sus usos - Google Patents

Diacuerpos heterodimericos biespecificos y sus usos

Info

Publication number
PE20170286A1
PE20170286A1 PE2016002813A PE2016002813A PE20170286A1 PE 20170286 A1 PE20170286 A1 PE 20170286A1 PE 2016002813 A PE2016002813 A PE 2016002813A PE 2016002813 A PE2016002813 A PE 2016002813A PE 20170286 A1 PE20170286 A1 PE 20170286A1
Authority
PE
Peru
Prior art keywords
subdomain
domain
diacbodies
bispecific heterodimeric
heterodimer
Prior art date
Application number
PE2016002813A
Other languages
English (en)
Spanish (es)
Inventor
Chad Michael May
Adam Reid Root
William A Brady
Lioudmila Gennadievna Tchistiakova
Lidia Mosyak
Laird Bloom
Paul A Moore
Leslie S Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20170286A1 publication Critical patent/PE20170286A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2016002813A 2014-07-01 2015-06-26 Diacuerpos heterodimericos biespecificos y sus usos PE20170286A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019762P 2014-07-01 2014-07-01
US201562148920P 2015-04-17 2015-04-17

Publications (1)

Publication Number Publication Date
PE20170286A1 true PE20170286A1 (es) 2017-03-30

Family

ID=53718063

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002813A PE20170286A1 (es) 2014-07-01 2015-06-26 Diacuerpos heterodimericos biespecificos y sus usos

Country Status (17)

Country Link
US (2) US9884921B2 (cg-RX-API-DMAC7.html)
EP (1) EP3164417A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017520575A (cg-RX-API-DMAC7.html)
KR (1) KR20170010863A (cg-RX-API-DMAC7.html)
CN (1) CN106661119A (cg-RX-API-DMAC7.html)
AU (2) AU2015283704A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016030740A2 (cg-RX-API-DMAC7.html)
CA (1) CA2895659A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017000016A2 (cg-RX-API-DMAC7.html)
IL (1) IL249889A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016017393A (cg-RX-API-DMAC7.html)
PE (1) PE20170286A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016502491A1 (cg-RX-API-DMAC7.html)
RU (1) RU2016151645A (cg-RX-API-DMAC7.html)
SG (1) SG11201609707WA (cg-RX-API-DMAC7.html)
TW (2) TW201936638A (cg-RX-API-DMAC7.html)
WO (1) WO2016001810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725819C2 (ru) 2014-12-05 2020-07-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
SI3283524T1 (sl) * 2015-04-17 2023-06-30 Amgen Research (Munich) Gmbh Bispecifični konstrukti protiteles za CDH3 in CD3
EP3322735A4 (en) 2015-07-15 2019-03-13 Zymeworks Inc. ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
MX2018012648A (es) 2016-04-28 2019-01-30 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos.
AU2017303205B2 (en) * 2016-07-29 2024-08-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity
CN106496331B (zh) * 2016-11-08 2020-03-13 北京智岭生物医药科技有限公司 一种FSH-Fc融合蛋白及其制备方法和用途
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP7205995B2 (ja) * 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
KR102367658B1 (ko) * 2017-03-29 2022-02-25 타이페이 메디컬 유니이버시티 항원 특이적 t 세포 및 그의 용도
CN108866635B (zh) * 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
SG10201913194WA (en) * 2017-06-02 2020-03-30 Pfizer Recombinant robo2 proteins, compositions, methods and uses thereof
KR20250065933A (ko) * 2017-06-22 2025-05-13 재단법인 생물기술개발중심 표적 세포-의존적 T 세포 관여 및 활성화 비대칭 헤테로다이머 Fc-ScFv 융합 항체 포맷 및 암 치료에서 그 사용
CN111108202B (zh) 2017-09-29 2024-10-22 中外制药株式会社 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
KR101973060B1 (ko) 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
SG11202003833TA (en) 2017-11-01 2020-05-28 Chugai Pharmaceutical Co Ltd Antibody variant and isoform with lowered biological activity
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3759129A1 (en) 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
CN112437672A (zh) * 2018-05-07 2021-03-02 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN113286634A (zh) 2018-05-23 2021-08-20 辉瑞公司 对gucy2c特异性的抗体及其用途
TWI793325B (zh) 2018-05-23 2023-02-21 美商輝瑞大藥廠 對cd3具特異性之抗體及其用途
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EP3954707A1 (en) * 2018-12-21 2022-02-16 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable bispecific antibodies and uses thereof
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
CN113416258B (zh) * 2019-10-24 2023-08-29 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof
IL293351A (en) 2019-12-18 2022-07-01 Pfizer Once daily cancer treatment regimen with a prmt5 inhibitor
US20240209061A1 (en) 2020-03-09 2024-06-27 Pfizer Inc. Fusion proteins and uses thereof
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
AU2021271318B2 (en) 2020-05-13 2025-10-30 Pfizer Inc. Methods, therapies and uses for treating cancer
PH12023550139A1 (en) 2020-07-17 2024-06-24 Pfizer Therapeutic antibodies and their uses
MX2023003034A (es) 2020-09-14 2023-04-10 Pfizer Metodos, terapias y usos para tratar el cancer.
US20240034786A1 (en) * 2020-12-10 2024-02-01 WuXi Biologics Ireland Limited An antibody against p-cadherin and uses thereof
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
PE20250875A1 (es) 2022-06-17 2025-03-28 Pfizer Variantes il-12, anticuerpos anti-pd1, proteinas de fusion y usos de estos
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
CN119585286A (zh) 2022-07-05 2025-03-07 辉瑞大药厂 吡啶并[4,3-d]嘧啶化合物
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
KR20250165440A (ko) 2023-04-05 2025-11-25 화이자 인코포레이티드 피리도[4,3-d]피리미딘 화합물
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2025032521A1 (en) 2023-08-10 2025-02-13 Pfizer Inc. Methods, therapies and uses for treating cancer
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
WO2025109003A1 (en) 2023-11-21 2025-05-30 3B Pharmaceuticals Gmbh P-cadherin ligands

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382317D1 (de) 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1991001752A1 (en) 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5811267A (en) 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0628078B1 (en) 1992-12-11 1999-12-08 The Dow Chemical Company Multivalent single chain antibodies
JP3695467B2 (ja) 1993-02-04 2005-09-14 ボレアン ファーマ エー／エス タンパクを再生するための改良された方法
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
JP2001500475A (ja) 1996-07-12 2001-01-16 マクギル ユニバーシティ 細胞接着を調節するための化合物および方法
ATE253593T1 (de) 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
AU6537798A (en) 1997-03-14 1998-10-12 Denise Casentini-Borocz Targeted cytolysis of cancer cells
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
US6485910B1 (en) 1998-02-09 2002-11-26 Incyte Genomics, Inc. Ras association domain containing protein
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
DE69909459T2 (de) 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US6534633B1 (en) 1998-10-21 2003-03-18 Altor Bioscience Corporation Polyspecific binding molecules and uses thereof
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
DE19905048A1 (de) 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
AU2001257206B2 (en) 2000-04-26 2006-10-05 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040053245A1 (en) 2001-02-05 2004-03-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20050118164A1 (en) 2001-03-09 2005-06-02 William Herman Targeted ligands
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
CA2445611A1 (en) 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
US20040241703A1 (en) 2002-08-19 2004-12-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
US20040018493A1 (en) 2002-07-12 2004-01-29 Anastasio Alison E. Haplotypes of the CD3E gene
EP1541588A4 (en) 2002-07-18 2007-09-12 Cellfree Sciences Co Ltd SINGLE CHAIN ANTIBODIES AND USE THEREOF
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
WO2004044000A2 (en) 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006524991A (ja) 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
AU2004247737B2 (en) 2003-06-11 2009-04-23 Wyeth Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof
AU2004252170B2 (en) 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20070037204A1 (en) 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005028507A1 (en) 2003-09-24 2005-03-31 Monash University CRYSTAL STRUCTURE OF CD3ϵϜ/OKT3 COMPLEX
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
BRPI0511782B8 (pt) 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP2311983A1 (en) 2005-02-10 2011-04-20 Oncotherapy Science, Inc. Method of treating bladder cancer using siRNA
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9296816B2 (en) * 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
EP1877430A2 (en) 2005-04-28 2008-01-16 McGill University Compounds and methods for modulating cadherin-mediated processes
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
EP1933868A2 (en) 2005-09-12 2008-06-25 NovImmune SA Anti-cd3 antibody formulations
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
ZA200805400B (en) 2005-12-21 2009-09-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
WO2007075672A2 (en) 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
JP2009528257A (ja) * 2006-02-28 2009-08-06 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法
WO2007106507A2 (en) 2006-03-14 2007-09-20 Petrie Howard T Detection of gene expression in mixed sample or tissue
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
TWI494319B (zh) 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
SG182234A1 (en) * 2007-04-03 2012-07-30 Amgen Res Munich Gmbh Cross-species-specific cd3-epsilonbinding domain
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
EP2164508B1 (en) 2007-06-04 2014-01-08 Rappaport Family Institute for Research in the Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
CA2694488A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
MX2010002018A (es) 2007-08-20 2010-05-27 Oncotherapy Science Inc Peptido de cdh3 y agente medicinal que comprende al mismo.
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
WO2009055937A1 (en) 2007-11-01 2009-05-07 The Royal Institution For The Advancement Of Learning/Mcgill University Altered n-cadherin processing in tumor cells by furln and proproteln convertase 5a (pc5a)
EA023031B1 (ru) 2007-11-30 2016-04-29 Глаксо Груп Лимитед Антиген-связывающая конструкция и ее применение
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
ES2534437T3 (es) 2008-06-30 2015-04-22 Oncotherapy Science, Inc. Anticuerpos anti-CDH3 marcados con etiqueta de radioisótopo y usos de los mismos
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
RU2547600C2 (ru) 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
WO2010037837A2 (en) 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
AU2009299792B2 (en) 2008-10-01 2015-07-16 Amgen Research (Munich) Gmbh Cross-species-specific PSMAxCD3 bispecific single chain antibody
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
WO2010040545A1 (en) 2008-10-06 2010-04-15 Novoplant Gmbh Proteolytically stable antibody formats
CN105218673A (zh) 2008-10-10 2016-01-06 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
CA2760642A1 (en) 2009-05-01 2010-11-04 The University Of Tokyo Anti-cadherin antibody
BRPI1007602A2 (pt) 2009-05-27 2016-02-16 Hoffmann La Roche "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110064743A1 (en) 2009-09-09 2011-03-17 Hammond Philip W Human anti-cancer antibodies
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US20120269826A1 (en) 2009-10-20 2012-10-25 Mckee Charlotte Anti-cd3 antibody dosing in autoimmune disease
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2011071541A2 (en) 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents
TW201130511A (en) 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
US20110165161A1 (en) 2009-12-23 2011-07-07 Shih-Yao Lin Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
CN102014475B (zh) 2010-01-08 2012-01-04 华为技术有限公司 资源映射、码分复用方法及装置
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
RS57008B1 (sr) 2010-02-10 2018-05-31 Fujifilm Ri Pharma Co Ltd Anti-kadherin antitelo obeleženo radioaktivnim metalom
PL2361936T3 (pl) 2010-02-25 2016-10-31 Cząsteczka wiążąca antygen i jej zastosowania
US8569450B2 (en) 2010-03-03 2013-10-29 Health Research Inc. CD3 epsilon immunogens and antibodies
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
BR112012028010A2 (pt) 2010-05-03 2017-09-26 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
EP2601216B1 (en) 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
RU2013110889A (ru) 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
CA2814040C (en) 2010-10-08 2021-03-23 Joshua Michael Donaldson A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
JP2014015396A (ja) 2010-10-29 2014-01-30 Perseus Proteomics Inc 高い親和性を有する抗ｃｄｈ３抗体
JP6006640B2 (ja) 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
TR201815863T4 (tr) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
EP2686348B1 (en) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
EP2688591A4 (en) 2011-03-22 2014-10-01 Baylor Res Inst TARGETING DENDRITIC CELLS FOR A TUBERCULOSIS VACCINE
EP2688592A4 (en) 2011-03-25 2015-07-22 Baylor Res Inst Compositions and methods for immunization against the hepatitis C virus
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
ES2605784T3 (es) 2011-05-21 2017-03-16 Macrogenics, Inc. Dominios de enlazamiento a suero desinmunizados y su uso para extender la vida media en suero
CN107722124A (zh) 2011-05-21 2018-02-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
SG10201604279TA (en) 2011-05-27 2016-07-28 Hoffmann La Roche Dual targeting
BR112013031762A2 (pt) 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
JPWO2012176765A1 (ja) 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
US20140242081A1 (en) 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
CN103687879B (zh) 2011-07-22 2016-05-04 阿菲姆德农业医药公司 多价抗原结合fv分子
CA2844538C (en) 2011-08-23 2020-09-22 Roche Glycart Ag Bispecific antigen binding molecules
MX2014001799A (es) 2011-08-23 2014-03-31 Roche Glycart Ag Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
MX356947B (es) 2011-08-23 2018-06-20 Roche Glycart Ag Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
EA030147B1 (ru) 2011-08-23 2018-06-29 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HUE033245T2 (hu) 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
EP4458859A3 (en) 2012-04-04 2025-01-22 Perseus Proteomics Inc. Conjugate of anti-cdh3 (p-cadherin) antibody and drug
US10202452B2 (en) 2012-04-20 2019-02-12 Aptevo Research And Development Llc CD3 binding polypeptides
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US10647756B2 (en) * 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies

Also Published As

Publication number Publication date
WO2016001810A1 (en) 2016-01-07
US9884921B2 (en) 2018-02-06
CN106661119A (zh) 2017-05-10
TWI659042B (zh) 2019-05-11
IL249889A0 (en) 2017-03-30
BR112016030740A2 (pt) 2018-02-20
PH12016502491A1 (en) 2017-03-22
MX2016017393A (es) 2017-09-05
JP2017520575A (ja) 2017-07-27
AU2018274919A1 (en) 2019-01-03
EP3164417A1 (en) 2017-05-10
TW201612194A (en) 2016-04-01
RU2016151645A (ru) 2018-08-03
RU2016151645A3 (cg-RX-API-DMAC7.html) 2019-02-20
KR20170010863A (ko) 2017-02-01
AU2015283704A1 (en) 2016-12-15
CO2017000016A2 (es) 2017-05-19
CA2895659A1 (en) 2016-01-01
SG11201609707WA (en) 2017-01-27
US20160002357A1 (en) 2016-01-07
US20180155452A1 (en) 2018-06-07
TW201936638A (zh) 2019-09-16

Similar Documents

Publication Publication Date Title
PE20170286A1 (es) Diacuerpos heterodimericos biespecificos y sus usos
AR131695A2 (es) Anticuerpo que se une a miostatina latente y ácido nucleico que lo codifica
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
CR20170079A (es) Agentes de unión a cd123 y usos de estos
PE20171383A1 (es) Receptores de antigeno quimericos anti-dll3 y metodos de uso
MX2016013767A (es) Anticuerpos humanizados contra cd269 (bcma).
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
CR20180065A (es) Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
CO2018000976A2 (es) Constructos de anticuerpo para cd70 y cd3
PE20181066A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
MX2018009386A (es) Constructos de anticuerpo biespecificos para psma y cd3 que se ligan a celulas t.
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
MX375524B (es) Anticuerpos anti-axl.
MX2016010128A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
DOP2019000064A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
MX2023002379A (es) Proteinas de fusion de union a dr5 multivalentes y multiespecificas.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.